Legend Biotech Corporation ( NASDAQ:LEGN ), a global leader in cell therapy, reported its first quarter 2024 unaudited financial results and key corporate highlights. The company made significant progress in the first quarter, with label expansions for CARVYKTI in the U.S., Europe, and Brazil, which have changed the treatment paradigm for multiple myeloma and...